Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$41.07
+3.3%
$35.63
$1.72
$54.30
$243.14M1.01362,258 shs26,967 shs
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
$8.17
-1.3%
$8.66
$4.44
$11.80
$170.70M-0.25133,694 shs66,402 shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$5.58
+3.5%
$4.13
$2.41
$10.37
$417.81M2.341.20 million shs1.28 million shs
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
$11.00
$11.00
$0.00
$12.48
$62.26M-0.112 shs99 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
+3.29%+1.56%+20.02%+3.74%+1,011.50%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-1.33%+1.11%-5.44%-7.79%+18.41%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
+3.53%+1.09%+11.16%+118.82%-42.12%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
0.00%0.00%0.00%0.00%+10.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.4039 of 5 stars
3.42.00.00.03.12.50.0
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
3.3264 of 5 stars
3.50.00.00.04.45.00.6
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.2825 of 5 stars
4.61.00.00.03.31.70.6
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.83
Moderate Buy$60.0046.09% Upside
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
3.00
Buy$17.00108.08% Upside
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.17
Buy$15.10170.61% Upside
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VHAQ, SLDB, NVCT, and MNPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$74.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/23/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
6/17/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
5/22/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$16.00
5/19/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $10.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/A$9.02 per shareN/A
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/AN/AN/AN/A$0.50 per shareN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.09M53.46N/AN/A$3.43 per share1.63
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$19M-$1.13N/AN/AN/AN/A-148.83%-95.60%8/5/2025 (Estimated)
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
-$610KN/A0.00N/AN/AN/AN/AN/A

Latest VHAQ, SLDB, NVCT, and MNPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.51N/AN/AN/AN/AN/A
8/8/2025N/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.47N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$0.25N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.53-$0.59-$0.06-$0.59N/AN/A
5/13/2025Q1 2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.65-$0.38+$0.27-$0.38N/AN/A
5/6/2025Q1 2025
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$0.30-$0.27+$0.03-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/AN/A
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/A
36.91
36.91
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/A
3.28
3.28
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
10.89
10.89
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1.83%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
96.77%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
22.14%

Insider Ownership

CompanyInsider Ownership
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
20.50%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
30.52%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
1.90%
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
75.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
106.12 million4.86 millionNot Optionable
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
820.89 million14.52 millionNot Optionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.51 million76.04 millionOptionable
Viveon Health Acquisition Corp. stock logo
VHAQ
Viveon Health Acquisition
25.66 million1.40 millionNot Optionable

Recent News About These Companies

Viveon Health Acquisition Corp
Clearday, Inc. (CLRD)
VHAQ-R Viveon Health Acquisition Corp.
Viveon Health Acquisition Corp. (VHAQ-RT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Monopar Therapeutics stock logo

Monopar Therapeutics NASDAQ:MNPR

$41.07 +1.31 (+3.29%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$41.61 +0.54 (+1.31%)
As of 07/16/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Nuvectis Pharma stock logo

Nuvectis Pharma NASDAQ:NVCT

$8.17 -0.11 (-1.33%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$8.78 +0.61 (+7.47%)
As of 06:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$5.58 +0.19 (+3.53%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$5.78 +0.20 (+3.58%)
As of 07:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Viveon Health Acquisition stock logo

Viveon Health Acquisition NYSE:VHAQ

Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.